17,261 trials
Prostate Cancer · Prostatic Neoplasms · Neoplasms, Prostate
Primary: Changes From Baseline to After Surgery of Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Infiltrates — 132.2; 153.7; 105.1; 140.5…
Endometriosis
Primary: Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24 — -0.11; -1.29; -0.99 percent change
Solar Urticaria
Primary: Proportion of Patients With Remission of Solar Urticaria Under Experimental Conditions (Phototesting) — 2 Participants
Depression · Mood Disorders · Major Depresssion
Primary: MADRS Score - Baseline — 1.17; 1.48; 33.83; 31.82 units on a scale
Substance Misuse · Interpersonal Conflict · Neuroendocrine Reactivity
Primary: Change in Frequency of Distress Maintaining Attributions — .81; -.48 distress maintaining attributions
Acute Myeloid Leukemia
Primary: Number of Participants That Achieved Complete Remission — 20 Participants
Frailty Syndrome
Primary: Change in the Short Physical Performance Battery (SPPB) — 0.6; 2.4 units on a scale
Metastatic Prostate Cancer
Primary: Recommended Phase 2 Dose (RP2D) — 25 mg
The Frailty Syndrome
Primary: Treatment Emergent Adverse Events — 1; 0; 1; 0 Events
Multiple Myeloma
Primary: Cmax (Pharmacokinetics) — 7380 ng/ml
Alopecia Areata · Alopecia Totalis · Alopecia Universalis
Primary: Percent Change in Severity of Alopecia Tool (SALT) Score — 10 percent change
B-cell Adult Acute Lymphoblastic Leukemia (ALL) · Ph-positive Adult Acute Lymphoblastic Leukemia (ALL) · Recurrent Adult Acute Lymphoblastic Leukemia (ALL)
Primary: Response Rate (RR) — 11 Participants
Infectious Diarrhoea
Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours
Insomnia · Fatigue
Primary: Insomnia Severity Index (ISI) — 16.3; 14.6; 13.5; 12.1 units on a scale
Vulvovaginitis · Yeast Infection · Yeast Infection Vaginal
Primary: Clinical Outcome Assessed at Test of Cure Visit — 13; 12; 24; 12 Participants